Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) Research & Development (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Research & Development for 4 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 155.0% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Dec 2025, up 41.03% year-over-year, with the annual reading at $16.7 million for FY2025, 41.03% up from the prior year.
  • Research & Development hit $4.9 million in Q4 2025 for Coya Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.2 million in Q1 2025 to a low of $708032.0 in Q4 2022.
  • Historically, Research & Development has averaged $2.4 million across 4 years, with a median of $1.8 million in 2023.
  • Biggest five-year swings in Research & Development: fell 26.21% in 2023 and later skyrocketed 327.56% in 2024.
  • Year by year, Research & Development stood at $708032.0 in 2022, then soared by 127.34% to $1.6 million in 2023, then grew by 20.37% to $1.9 million in 2024, then surged by 155.0% to $4.9 million in 2025.
  • Business Quant data shows Research & Development for COYA at $4.9 million in Q4 2025, $2.9 million in Q3 2025, and $3.7 million in Q2 2025.